A Systematic Review of Aspirin in Primary Prevention: Is It Time for a New Approach?
Conclusion
Available data on aspirin in primary prevention suggest a modest benefit for patients at high risk of CVD, and a promising benefit for those at risk of cancer. Future studies should help to elucidate whether the benefit of aspirin outweighs risk in appropriate patient groups.
Source: American Journal of Cardiovascular Drugs - Category: Cardiology Source Type: research
More News: Aspirin | Bleeding | Cancer | Cancer & Oncology | Cardiology | Cardiovascular | Heart | Study | Websites